Last updated on April 2019

A Study of PDR001 in Combination With LCL161 Everolimus or Panobinostat


Brief description of study

The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

Clinical Study Identifier: NCT02890069

Find a site near you

Start Over

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Novartis Investigative Site

Manchester, United Kingdom
  Connect »

Novartis Investigative Site

Santa Monica, CA United States
  Connect »

Novartis Investigative Site

Baltimore, MD United States
  Connect »

Novartis Investigative Site

Ann Arbor, MI United States
  Connect »

Novartis Investigative Site

Saint Louis, MO United States
  Connect »

Novartis Investigative Site

Houston, TX United States
  Connect »

Novartis Investigative Site

San Antonio, TX United States
  Connect »

Novartis Investigative Site

Salt Lake City, UT United States
  Connect »

Novartis Investigative Site

Seattle, WA United States
  Connect »